Clinical trial · Observational
Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients
Observational Study on the Effectiveness and Safety of Vaccination Anti-SARS-CoV2 in Patients With Lung Cancer
NCT05009030CI-TRIAL-00059967VAC-CaPcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Observational and multicenter retrospective study of data collection in hospital centers throughout the Spanish geography. This study aims to be nationwide in order to study general common variables of the patients, as well as the correlation with the cancer treatments received.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Covid19 | — | UNRESOLVED | — |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| COVID-19 vaccine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Study group
- description
- Patients with lung cancer of any histology and stage who receive an anti-COVID-19 vaccine approved by the health authorities. Patients would be eligible whether they have suffered from SARS-CoV2 infection or have not had COVID19.
- interventionNames
- Drug: COVID-19 vaccine
Primary outcomes (2)
- measure
- Determine the efficacy of the COVID19 vaccine
- timeFrame
- From the date of the last dose of the vaccine until three months later
- description
- Analyze patients who do not become infected with COVID-19 after being vaccinated
- measure
- Incidence of COVID-19 vaccine-Emergent Adverse Events (Safety and Tolerability)
- timeFrame
- From the date of first dose of COVID-19 vaccine through 90 days after the final administration of the drug
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with lung cancer of any stage and histology who have or have not contracted COVID-19 and who have been vaccinated with an EMA approved COVID-19 vaccine. * Age equal to or greater than 18 years Exclusion Criteria: * Patients who have not received an EMA approved COVID-19 vaccine.
References
Publications (0)
Data not yet available
No reference posted for this study.